Physician profile
Malwinder Sidhu
NPI 1720189095
$3,603.74
in general payments reported to CMS, 2019-2025
21 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,060 · 2024: $1,247 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,603.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,654.67 | 2023-2025 | Rinvoq, Linzess, Viberzi |
| Genzyme Corporation | $430.94 | 2023-2025 | |
| Enterra Medical, INC. | $339.59 | 2025 | |
| Janssen Biotech, INC. | $243.47 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $210.55 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.04 | 2023-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $112.38 | 2023-2025 | Sutab, Suflave |
| Redhill Biopharma INC. | $71.17 | 2023-2024 | Talicia, Aemcolo, Movantik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.14 | 2023-2024 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $59.25 | 2024 | |
| Ardelyx, INC. | $51.33 | 2023 | Ibsrela |
| Aimmune Therapeutics, INC. | $39.66 | 2024-2025 | Vowst |
| Celltrion USA INC. | $37.17 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $25.61 | 2023 | Dupixent |
| Orphalan INC | $23.55 | 2025 | Cuvrior |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21.47 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $20.14 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $19.13 | 2023 | Rebyota |
| Capsovision, INC. | $15.98 | 2024 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $15.83 | 2024 | Dificid |
| Digestive Care, INC. | $15.67 | 2024 | Pertzye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malwinder Sidhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.